Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q2 2025 conference call for investors ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Novavax ( NASDAQ: NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company declined 1.73% to $6.54 on Friday afternoon. The vaccine maker lost close ...

Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

Shares of European pharmaceutical companies sold off on Friday after President Donald Trump issued letters to 17 companies, ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the company's Board of Directors, effective today, August 1, 2025.

Global stocks weakened on Friday after Donald Trump hit dozens of countries with tariffs, as the US president pushed ahead ...